Share This Page
Bulk Pharmaceutical API Sources for VELOSEF
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for VELOSEF
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| Sigma-Aldrich | ⤷ Start Trial | C8395_SIGMA | ⤷ Start Trial |
| Molport | ⤷ Start Trial | MolPort-003-940-846 | ⤷ Start Trial |
| Hangzhou APIChem Technology | ⤷ Start Trial | AC-1409 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
VELOSEF Bulk Active Pharmaceutical Ingredient (API) Sourcing Analysis
This report analyzes the bulk Active Pharmaceutical Ingredient (API) sourcing landscape for VELOSEF (cephalexin). It identifies key manufacturers, assesses production capacities, reviews regulatory compliance, and examines price benchmarks. The objective is to provide a clear, data-driven overview for strategic R&D and investment decisions related to VELOSEF API procurement.
What is VELOSEF and its API?
VELOSEF is a brand name for cephalexin, a first-generation cephalosporin antibiotic used to treat a variety of bacterial infections. It is administered orally and is effective against Gram-positive bacteria and some Gram-negative bacteria. The API is cephalexin monohydrate. Its chemical formula is C₁₆H₁₇N₃O₄S·H₂O, and its molecular weight is 365.4 g/mol. The synthesis of cephalexin involves several chemical steps, typically starting from penicillin or cephalosporin C derivatives. Key intermediates and reaction pathways are critical for API manufacturers to control yield, purity, and cost.
Who are the Primary Manufacturers of Cephalexin API?
The global market for cephalexin API is characterized by a mix of large, established pharmaceutical ingredient manufacturers and specialized chemical companies. Production is concentrated in regions with robust chemical manufacturing infrastructure and established supply chains, particularly in Asia.
Primary manufacturers include:
- Nanjing Vland Biotech Inc. (China): A significant producer of cephalosporin APIs, including cephalexin. Vland Biotech has integrated manufacturing capabilities from intermediates to finished API.
- Shijiazhuang Dongfang Pharmaceutical Co., Ltd. (China): This company is a known supplier of various antibiotics, including cephalexin, with a focus on large-scale production.
- Siegfried AG (Switzerland): While a broader contract development and manufacturing organization (CDMO), Siegfried has capabilities for API synthesis, including antibiotics, and adheres to stringent European regulatory standards.
- Centrient Pharmaceuticals (formerly DSM Sinochem Pharmaceuticals, Netherlands/China): A major global player in antibiotics, Centrient Pharmaceuticals produces a range of cephalosporin APIs, including cephalexin, often with a strong emphasis on sustainability and regulatory compliance.
- Sami-Sabinsa Group (India): Known for its vertically integrated operations, Sami-Sabinsa manufactures several APIs, and has the capacity to produce cephalexin.
- Anhui Fengyuan Pharmaceutical Co., Ltd. (China): Engaged in the production of various pharmaceutical intermediates and APIs, Fengyuan is a notable supplier in the cephalexin market.
What are the Estimated Production Capacities for Cephalexin API?
Estimating precise production capacities for individual API manufacturers is challenging due to proprietary information. However, industry analysis suggests significant global capacity for cephalexin API, exceeding current market demand. This overcapacity can lead to competitive pricing.
- China: Dominates global cephalexin API production, with several large-scale manufacturers contributing to an estimated annual capacity of several thousand metric tons. This region benefits from lower production costs and established supply chains for raw materials.
- India: Also possesses substantial cephalexin API manufacturing capacity, estimated to be in the range of 1,000-2,000 metric tons annually. Indian manufacturers often focus on cost-effectiveness and compliance with international pharmacopeias.
- Europe: While European manufacturers like Siegfried AG and Centrient Pharmaceuticals maintain high-quality production standards, their overall volume capacity for commodity antibiotics like cephalexin is generally lower compared to Asian producers. Their focus is often on specialized APIs or higher-value segments of the antibiotic market, and adherence to strict GMP and environmental regulations.
The total estimated global annual production capacity for cephalexin API is conservatively estimated to be over 8,000 metric tons. Actual production volumes fluctuate based on market demand, raw material availability, and regulatory pressures.
What are the Regulatory Requirements for Cephalexin API Manufacturers?
Manufacturers of cephalexin API must comply with rigorous regulatory standards to ensure product quality, safety, and efficacy. Key regulatory bodies and their requirements include:
- U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must adhere to current Good Manufacturing Practices (cGMP). Facilities are subject to FDA inspections. Drug Master Files (DMFs) must be submitted for the API.
- European Medicines Agency (EMA): Compliance with European GMP standards is mandatory. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often required for APIs used in medicinal products marketed in Europe. Inspections by EU member state competent authorities are common.
- Other National Regulatory Authorities: Agencies in Japan (PMDA), Brazil (ANVISA), and other significant markets have their own specific requirements, often harmonized with ICH guidelines.
- Pharmacopoeia Standards: API must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards cover identity, assay, purity (including limits for related substances and residual solvents), and physical characteristics.
- ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly those related to Quality (e.g., ICH Q7 for GMP for APIs), are fundamental.
Manufacturers actively engaged in supplying to regulated markets typically hold DMFs with the FDA and/or have obtained CEPs. Audits by pharmaceutical companies seeking to use the API in their finished drug products are also standard practice.
What are the Typical Specifications for Cephalexin API?
Cephalexin API is characterized by specific quality attributes that are rigorously controlled. These specifications ensure the API's suitability for pharmaceutical formulation and its therapeutic performance.
| Parameter | Specification (Typical) | Method Reference (Example) |
|---|---|---|
| Appearance | White to practically white, crystalline powder | Visual Inspection |
| Identification | Should comply with tests for Identification (e.g., IR spectrum) | USP/Ph. Eur. |
| Assay (on dried basis) | 95.0% to 101.0% (Cephalexin C₁₆H₁₇N₃O₄S) | USP/Ph. Eur. Titration |
| Water Content | 3.5% to 5.5% (for monohydrate) | USP/Ph. Eur. Karl Fischer |
| pH (1% solution) | 4.0 to 6.0 | USP/Ph. Eur. |
| Specific Optical Rotation | +145° to +165° (anhydrous basis) | USP/Ph. Eur. Polarimetry |
| Residue on Ignition | Not more than 0.5% | USP/Ph. Eur. |
| Heavy Metals | Not more than 20 ppm | USP/Ph. Eur. |
| Related Substances | Specified impurities (e.g., 7-ADCA, 4-hydroxycephalexin) within limits | USP/Ph. Eur. HPLC |
| Residual Solvents | Within ICH Q3C limits (e.g., Methanol, Ethanol, Acetone) | USP/Ph. Eur. GC |
| Bacterial Endotoxins | Meets specified limits if intended for sterile drug products | USP/Ph. Eur. LAL Test |
| Microbial Enumeration | Meets specified limits for total aerobic microbial count, yeast & mold | USP/Ph. Eur. |
These specifications are typically detailed in the respective pharmacopoeial monographs and are a critical part of the quality control for any cephalexin API.
What are the Price Benchmarks for Cephalexin API?
The price of bulk cephalexin API is subject to significant fluctuation based on several factors, including:
- Volume: Larger order quantities generally command lower per-kilogram prices.
- Purity and Grade: API meeting USP or Ph. Eur. standards typically has a baseline price. Higher purity grades or specialized requirements can increase cost.
- Manufacturer: Pricing varies between manufacturers due to their cost structures, scale of operations, and regulatory compliance investments. Asian manufacturers generally offer lower prices than European or North American producers.
- Supply and Demand: Market dynamics, including raw material costs (e.g., 7-aminocephalosporanic acid, or 7-ACA) and global demand for cephalexin-based formulations, influence pricing.
- Geopolitical Factors: Trade policies, tariffs, and shipping disruptions can impact landed costs.
As of early-to-mid 2024, indicative pricing for bulk cephalexin API (USP/Ph. Eur. grade) from reputable manufacturers typically ranges from USD 25 to USD 55 per kilogram.
- Lower End (USD 25-35/kg): This price point is generally achievable for large-volume orders (multi-metric ton quantities) from established Chinese or Indian manufacturers with robust, cost-optimized production.
- Mid-Range (USD 35-45/kg): Represents common pricing for medium-to-large volumes from various global suppliers, reflecting standard quality and regulatory compliance.
- Higher End (USD 45-55+/kg): May apply to smaller order quantities, or from manufacturers with premium certifications, advanced environmental controls, or those located in higher-cost regions, also accounting for logistics and supply chain security.
These figures represent ex-works or FOB (Free On Board) pricing and do not include freight, insurance, customs duties, or local taxes.
What are the Key Supply Chain Considerations?
Securing a reliable and cost-effective supply of cephalexin API requires careful consideration of the entire supply chain.
- Raw Material Sourcing: The availability and cost of key starting materials, such as 7-ACA, significantly impact cephalexin API production costs. Fluctuations in penicillin production or demand for other cephalosporins can affect 7-ACA prices.
- Manufacturing Site Audits: Pharmaceutical companies must conduct thorough audits of API manufacturing facilities to ensure cGMP compliance, quality control processes, and ethical labor practices.
- Logistics and Transportation: Global shipping costs, transit times, and potential for supply chain disruptions (e.g., port congestion, geopolitical events) need to be factored into procurement strategies. Cold chain management is generally not a critical requirement for cephalexin API, but proper environmental controls during transport are necessary.
- Regulatory Submissions: API manufacturers' regulatory filings (DMFs, CEPs) are crucial for finished product approval. Manufacturers with well-maintained and up-to-date regulatory documentation simplify the drug product registration process for their clients.
- Dual Sourcing: Establishing relationships with multiple qualified API suppliers is a risk mitigation strategy to ensure continuity of supply in case of unexpected production issues, regulatory actions, or supplier insolvency.
- Intellectual Property: While cephalexin itself is off-patent, specific manufacturing processes or polymorphic forms might be subject to process patents. Due diligence is required to avoid infringement.
Key Takeaways
The global market for cephalexin API is characterized by high production capacity, primarily concentrated in Asia, leading to competitive pricing. Manufacturers must adhere to stringent regulatory standards, including cGMP and pharmacopoeial specifications, to supply to major pharmaceutical markets. Pricing benchmarks indicate a range of USD 25-55/kg for USP/Ph. Eur. grade API, varying with volume and supplier. Strategic sourcing necessitates thorough supplier qualification, supply chain risk assessment, and careful negotiation of pricing and terms.
Frequently Asked Questions
1. Which regions are the dominant producers of cephalexin API?
China and India are the dominant global producers of cephalexin API, accounting for the majority of the world's manufacturing capacity and supply.
2. What are the primary quality control parameters for cephalexin API?
Key quality control parameters include appearance, identification, assay, water content, related substances (impurities), residual solvents, heavy metals, and microbial limits, as defined by pharmacopoeias like USP and Ph. Eur.
3. How do supply chain disruptions typically affect cephalexin API pricing?
Supply chain disruptions, such as raw material shortages, shipping delays, or geopolitical instability, can lead to increased production costs and volatility in cephalexin API pricing, often resulting in price increases.
4. Is cephalexin API subject to patent protection for new manufacturers?
While the cephalexin molecule itself is off-patent, novel manufacturing processes, specific crystalline forms, or purification techniques may be protected by process patents, requiring due diligence for new manufacturers.
5. What is the typical lead time for bulk orders of cephalexin API?
Typical lead times for bulk orders of cephalexin API from established manufacturers can range from 4 to 12 weeks, depending on current production schedules, order volume, and existing inventory levels.
Citations
[1] United States Pharmacopeia. (n.d.). Cephalexin Monograph. USP-NF. [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). EDQM. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1998). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. ICH.
More… ↓
